Kneat.com Responds to Press Report

On May 11, 2026, Kneat.com publicly confirmed it is conducting a strategic review of alternatives, having formed a special committee of the board and engaged CIBC Capital Markets as financial advisor. The process began in February 2026, but no definitive agreement has been reached, and there is no assurance a transaction will result. The release is a direct response to recent press speculation.

The strategic review is a clear signal that management and the board see value unrecognized by the market and are open to a sale, merger, or other corporate event. For a company that has consistently delivered 25‑35% top‑line growth, hit $74 million ARR, turned adjusted EBITDA positive, and guided to cash‑flow breakeven in 2026, the stock price had fallen from a 52‑week high of $6.75 to as low as $3.30 by late March 2026 despite no fundamental deterioration. The gap between operational performance and market valuation makes an outright sale or take‑private a logical catalyst. The news is material because it introduces a potential value‑realization event that the market had not fully priced in; however, given the early stage and lack of definitive agreement, it is positive but not yet a game changer.

In the historical context, Kneat added multiple global enterprise customers (top pharma, biopharma, CDMOs, specialty chemicals), launched AI‑enhanced features, and maintained >115% net revenue retention. The most recent results (Feb 25, 2026) reaffirmed breakeven guided for full‑year 2026. The subsequent stock weakness—even after a string of contract wins—appears disconnected from fundamentals. The strategic review therefore represents a board‑level acknowledgment of that disconnect and a proactive step to surface value.

Kneat Solutions Inc. provides a cloud‑based digital validation platform (Kneat Gx) that replaces paper‑based processes in highly regulated life‑sciences, biopharma, and chemical manufacturing. The platform ensures data integrity, compliance, and audit readiness across Commissioning, Qualification & Validation (CQV), Computer System Validation (CSV), equipment validation, and electronic logbooks. It has been adopted by 8 of the top 10 pharmaceutical manufacturers and dozens of global CDMOs, packaging, and specialty‑chemical firms. The company was founded with a mission to digitize GxP validation, and its flagship Kneat Gx platform has become the de‑facto standard in the industry, as evidenced by a 98/100 G2 Satisfaction Score and a Net Promoter Score >70.